Establishment of a high-throughput detection system for DNA demethylating agents

References

• Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer. 2005;5:223–231. doi:10.1038/nrc1571.
   PubMed Web of Science ®Google Scholar
• Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54:716–727. doi:10.1016/j.molcel.2014.05.015.
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17(5):284–299. PMID:26972587.
   PubMed Web of Science ®Google Scholar
• Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–1068. doi:10.1038/nbt.1685.
   PubMed Web of Science ®Google Scholar
• Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28:1069–1078. doi:10.1038/nbt.1678.
   PubMed Web of Science ®Google Scholar
• Ronn T, Ling C DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes. Epigenomics. 2015;7:451–460. doi:10.2217/epi.15.7.
   PubMed Web of Science ®Google Scholar
• Dhanak D, Jackson P. Development and classes of epigenetic drugs for cancer. Biochem Biophys Res Commun. 2014;455:58–69. doi:10.1016/j.bbrc.2014.07.006.
   PubMed Web of Science ®Google Scholar
• Azad N, Zahnow CA, Rudin CM, et al. The future of epigenetic therapy in solid tumours–lessons from the past. Nat Rev Clin Oncol. 2013;10:256–266. doi:10.1038/nrclinonc.2013.42.
   PubMed Web of Science ®Google Scholar
• Jakovcevski M, Akbarian S. Epigenetic mechanisms in neurological disease. Nat Med. 2012;18:1194–1204. doi:10.1038/nm.2828.
   PubMed Web of Science ®Google Scholar
• Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2016;127:42–52. doi:10.1182/blood-2015-07-604512.
   PubMed Web of Science ®Google Scholar
• Shinjo K, Kondo Y Targeting cancer epigenetics: Linking basic biology to clinical medicine. Adv Drug Deliv Rev. 2015;95:56–64. doi:10.1016/j.addr.2015.10.006.
   PubMed Web of Science ®Google Scholar
• Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007;67:6400–6408. doi:10.1158/0008-5472.CAN-07-0251.
   PubMed Web of Science ®Google Scholar
• Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics. 2015;7:127. doi:10.1186/s13148-015-0157-2.
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia. 2015;29:760–769. doi:10.1038/leu.2014.244.
   PubMed Web of Science ®Google Scholar
• Issa JP, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16:1099–1110. doi:10.1016/S1470-2045(15)00038-8.
   PubMed Web of Science ®Google Scholar
• Foulks JM, Parnell KM, Nix RN, et al. Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen. 2012;17:2–17. doi:10.1177/1087057111421212.
   PubMed Web of Science ®Google Scholar
• Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005;25:4727–4741. doi:10.1128/MCB.25.11.4727-4741.2005.
   PubMed Web of Science ®Google Scholar
• Schubeler D. Function and information content of DNA methylation. Nature. 2015;517:321–326. doi:10.1038/nature14192.
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Yamaguchi L, Nakanishi M. Regulation of maintenance DNA methylation via histone ubiquitylation. J Biochem. 2016;159:9–15. doi:10.1093/jb/mvv113.
   PubMed Web of Science ®Google Scholar
• Lin RK, Wang YC. Dysregulated transcriptional and post-translational control of DNA methyltransferases in cancer. Cell Biosci. 2014;4:46. doi:10.1186/2045-3701-4-46.
   PubMed Web of Science ®Google Scholar
• Voss TC, Hager GL. Dynamic regulation of transcriptional states by chromatin and transcription factors. Nat Rev Genet. 2014;15:69–81. doi:10.1038/nrg3623.
   PubMed Web of Science ®Google Scholar
• Okochi-Takada E, Ichimura S, Kaneda A, et al. Establishment of a detection system for demethylating agents using an endogenous promoter CpG island. Mutat Res. 2004;568:187–194. doi:10.1016/j.mrfmmm.2004.08.011.
   PubMed Web of Science ®Google Scholar
• Cui Y, Hausheer F, Beaty R, et al. A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. Cancer Res. 2014;74:3834–3843. doi:10.1158/0008-5472.CAN-13-2287.
   PubMed Web of Science ®Google Scholar
• Lu Y, Chu A, Turker MS, et al. Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol Cell Biol. 2011;31:3339–3350. doi:10.1128/MCB.01121-10.
   PubMed Web of Science ®Google Scholar
• Okochi-Takada E, Nakazawa K, Wakabayashi M, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer. 2006;119:1338–1344. doi:10.1002/ijc.22025.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Takahashi S, McDonell N, et al. Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers. Cancer Res. 2008;68:2112–2121. doi:10.1158/0008-5472.CAN-07-5282.
   PubMed Web of Science ®Google Scholar
• Takeshima H, Yamashita S, Shimazu T, et al. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res. 2009;19:1974–1982. doi:10.1101/gr.093310.109.
   PubMed Web of Science ®Google Scholar
• Osada H. Introduction of new tools for chemical biology research on microbial metabolites. Biosci Biotechnol Biochem. 2010;74:1135–1140. doi:10.1271/bbb.100061.
   PubMed Web of Science ®Google Scholar
• Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65:6305–6311. doi:10.1158/0008-5472.CAN-04-2957.
   PubMed Web of Science ®Google Scholar
• Datta J, Ghoshal K, Denny WA, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 2009;69:4277–4285. doi:10.1158/0008-5472.CAN-08-3669.
   PubMed Web of Science ®Google Scholar
• Yoo J, Choi S, Medina-Franco JL. Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs. PLoS One. 2013;8:e62152. doi:10.1371/journal.pone.0062152.
   PubMed Web of Science ®Google Scholar
• Klisovic RB, Stock W, Cataland S, et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008;14:2444–2449. doi:10.1158/1078-0432.CCR-07-1320.
   PubMed Web of Science ®Google Scholar
• Kuck D, Caulfield T, Lyko F, et al. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther. 2010;9:3015–3023. doi:10.1158/1535-7163.MCT-10-0609.
   PubMed Web of Science ®Google Scholar
• Raynal NJ, Lee JT, Wang Y, et al. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Res. 2016;76:1494–505. doi:10.1158/0008-5472.CAN-14-2391.
   PubMed Web of Science ®Google Scholar
• Dahlin JL, Walters MA. The essential roles of chemistry in high-throughput screening triage. Future Med Chem. 2014;6:1265–1290. doi:10.4155/fmc.14.60.
   PubMed Web of Science ®Google Scholar
• Snyder RD, Green JW. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res. 2001;488:151–169. doi:10.1016/S1383-5742(01)00055-2.
   PubMed Web of Science ®Google Scholar
• Nagao M, Ochiai M, Okochi E, et al. LacI transgenic animal study: relationships among DNA-adduct levels, mutant frequencies and cancer incidences. Mutat Res. 2001;477:119–124. doi:10.1016/S0027-5107(01)00113-0.
   PubMed Web of Science ®Google Scholar
• Okonogi H, Stuart GR, Okochi E, et al. Effects of gender and species on spectra of mutation induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the lacI transgene. Mutat Res 1997;395:93–99.
   PubMed Web of Science ®Google Scholar
• MacPhee DG. Epigenetics and epimutagens: some new perspectives on cancer, germ line effects and endocrine disrupters. Mutat Res. 1998;400:369–379. doi:10.1016/S0027-5107(98)00046-3.
   PubMed Web of Science ®Google Scholar
• Holliday R, Ho T. DNA methylation and epigenetic inheritance. Methods. 2002;27:179–183. doi:10.1016/S1046-2023(02)00072-5.
   PubMed Web of Science ®Google Scholar